|
1
|
Sturm D, Bender S, Jones DT, Lichter P,
Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, et
al: Paediatric and adult glioblastoma: Multiform (epi)genomic
culprits emerge. Nat Rev Cancer. 14:92–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Auffinger B, Spencer D, Pytel P, Ahmed AU
and Lesniak MS: The role of glioma stem cells in chemotherapy
resistance and glioblastoma multiforme recurrence. Expert Rev
Neurother. 15:741–752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
de Faria GP, de Oliveira JA, de Oliveira
JG, Romano Sde O, Neto VM and Maia RC: Differences in the
expression pattern of P-glycoprotein and MRP1 in low-grade and
high-grade gliomas. Cancer Invest. 26:883–889. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin Y, Bin ZQ, Qiang H, Liang C, Hua C,
Jun D, Dong WA and Qing L: ABCG2 is related with the grade of
glioma and resistance to mitoxantone, a chemotherapeutic drug for
glioma. J Cancer Res Clin Oncol. 135:1369–1376. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bleau AM, Huse JT and Holland EC: The
ABCG2 resistance network of glioblastoma. Cell Cycle. 8:2936–2944.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang R, Saito R, Shibahara I, Sugiyama S,
Kanamori M, Sonoda Y and Tominaga T: Temozolomide reverses
doxorubicin resistance by inhibiting P-glycoprotein in malignant
glioma cells. J Neurooncol. 126:235–242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Singh MS and Lamprecht A: P-glycoprotein
inhibition of drug resistant cell lines by nanoparticles. Drug Dev
Ind Pharm. 42:325–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang N, Chen S, Deng J, Huang Q, Liao P,
Wang F and Cheng Y: Over-expression of S100A9 in human glioma and
in-vitro inhibition by aspirin. Eur J Cancer Prev. 22:585–595.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen S, Zhao H, Deng J, Liao P, Xu Z and
Cheng Y: Comparative proteomics of glioma stem cells and
differentiated tumor cells identifies S100A9 as a potential
therapeutic target. J Cell Biochem. 114:2795–2808. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng Y, Ng ES, Kwan YW, Lau CB, Cheung DW,
Koon JC, Zhang Z, Zuo Z, Leung PC, Fung KP and Lam FF: Cerebral
vasodilator properties of Danshen and Gegen: A study of their
combined efficacy and mechanisms of actions. Phytomedicine.
21:391–399. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Van Poppel PC, Breedveld P, Abbink EJ,
Roelofs H, van Heerde W, Smits P, Lin W, Tan AH, Russel FG, Donders
R, et al: Salvia miltiorrhiza root water-extract (Danshen)
has no beneficial effect on cardiovascular risk factors. A
Randomized Double-Blind Cross-Over Trial. PLoS One.
10:e01286952015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cai X, Chen Z, Pan X, Xia L, Chen P, Yang
Y, Hu H, Zhang J, Li K, Ge J, et al: Inhibition of angiogenesis,
fibrosis and thrombosis by tetramethylpyrazine: Mechanisms
contributing to the SDF-1/CXCR4 axis. PLoS One. 9:e881762014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin TH and Hsieh CL: Pharmacological
effects of Salvia miltiorrhiza (Danshen) on cerebral
infarction. Chin Med. 5:222010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo J, Song W, Yang G, Xu H and Chen K:
Compound danshen (Salvia miltiorrhiza) dripping pill for
coronary heart disease: An overview of systematic reviews. Am J
Chin Med. 43:25–43. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SH, Kim YS, Lee SJ and Lee BC: The
protective effect of Salvia miltiorrhiza in an animal model
of early experimentally induced diabetic nephropathy. J
Ethnopharmacol. 137:1409–1414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Huang Y, Zhao C, Qin X, Zhu Q, Chen
S and Qu J: Salvia miltiorrhiza injection on pulmonary heart
disease: A systematic review and meta-analysis. Am J Chin Med.
42:1315–1331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen X, Guo J, Bao J, Lu J and Wang Y: The
anticancer properties of Salvia miltiorrhiza Bunge
(Danshen): A systematic review. Med Res Rev. 34:768–794. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin LL, Hsia CR, Hsu CL, Huang HC and Juan
HF: Integrating transcriptomics and proteomics to show that
tanshinone IIA suppresses cell growth by blocking glucose
metabolism in gastric cancer cells. BMC Genomics. 16:412015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong Y, Li Y, Lu Y, Li L, Abdolmaleky H,
Blackburn GL and Zhou JR: Bioactive tanshinones in Salvia
miltiorrhiza inhibit the growth of prostate cancer cells in
vitro and in mice. Int J Cancer. 129:1042–1052. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Fu Q and Zhao W:
Tetramethylpyrazine inhibits osteosarcoma cell proliferation via
downregulation of NF-κB in vitro in vivo. Mol Med Rep.
8:984–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
|
23
|
Tivnan A, Zakaria Z, O'Leary C, Kögel D,
Pokorny JL, Sarkaria JN and Prehn JH: Inhibition of multidrug
resistance protein 1 (MRP1) improves chemotherapy drug response in
primary and recurrent glioblastoma multiforme. Front Neurosci.
9:2182015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Jonge-Peeters SD, Kuipers F, de Vries
EG and Vellenga E: ABC transporter expression in hematopoietic stem
cells and the role in AML drug resistance. Crit Rev Oncol Hematol.
62:214–226. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Andersson U, Malmer B, Bergenheim AT,
Brännström T and Henriksson R: Heterogeneity in the expression of
markers for drug resistance in brain tumors. Clin Neuropathol.
23:21–27. 2004.PubMed/NCBI
|
|
26
|
Agarwal S, Sane R, Gallardo JL, Ohlfest JR
and Elmquist WF: Distribution of gefitinib to the brain is limited
by P-glycoprotein (ABCB1) and breast cancer resistance protein
(ABCG2)-mediated active efflux. J Pharmacol Exp Ther. 334:147–155.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deeley RG and Cole SP: Substrate
recognition and transport by multidrug resistance protein 1
(ABCC1). FEBS Lett. 580:1103–1111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu K, Chen Z, Pan X, Yang Y, Tian S, Zhang
J, Ge J, Ambati B and Zhuang J: Tetramethylpyrazine-mediated
suppression of C6 gliomas involves inhibition of chemokine receptor
CXCR4 expression. Oncol Rep. 28:955–960. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu L, Li C, Li D, Wang Y, Zhou C, Shao W,
Peng J, You Y, Zhang X and Shen X: Cryptotanshinone inhibits human
glioma cell proliferation by suppressing STAT3 signaling. Mol Cell
Biochem. 381:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai J, Chen S, Zhang W, Zheng X, Hu S,
Pang C, Lu J, Xing J and Dong Y: Salvianolic acid A reverses
paclitaxel resistance in human breast cancer MCF-7 cells via
targeting the expression of transgelin 2 and attenuating PI3K/Akt
pathway. Phytomedicine. 21:1725–1732. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu T, To KK, Wang L, Zhang L, Lu L, Shen
J, Chan RL, Li M, Yeung JH and Cho CH: Reversal of P-glycoprotein
(P-gp) mediated multidrug resistance in colon cancer cells by
cryptotanshinone and dihydrotanshinone of Salvia
miltiorrhiza. Phytomedicine. 21:1264–1272. 2014. View Article : Google Scholar : PubMed/NCBI
|
